AbbVie
ABBV
$147.96
Share price
1.08%
Change (1 day)
-9.63%
Change (1 year)
Categories
The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol “ABBV”.
Revenue for AbbVie (ABBV)
Revenue in 2023 (TTM): $55.13 B
According to AbbVie's latest financial reports the company's current revenue (TTM) is $55.13 B. In 2022 the company made a revenue of $58.05 B an increase over the years 2021 revenue that were of $56.19 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for AbbVie from 2011 to 2023
Annual revenue
| Year | Revenue | Change |
|---|---|---|
| 2023 (TTM) | $55.13 B | -5.02% |
| 2022 | $58.05 B | 3.3% |
| 2021 | $56.19 B | 22.69% |
| 2020 | $45.80 B | 37.69% |
| 2019 | $33.26 B | 1.57% |
| 2018 | $32.75 B | 16.08% |
| 2017 | $28.21 B | 10.06% |
| 2016 | $25.63 B | 12.16% |
| 2015 | $22.85 B | 14.52% |
| 2014 | $19.96 B | 6.23% |
| 2013 | $18.79 B | 2.23% |
| 2012 | $18.37 B | 5.36% |
| 2011 | $17.44 B |
Revenue for similar companies or competitors
| Company | Revenue | Revenue differencediff. | Country |
|---|---|---|---|
 Pfizer PFE | $68.53 B | 24.30% | 🇺🇸 USA |
 Eli Lilly LLY | $32.07 B | -41.83% | 🇺🇸 USA |
 Amgen AMGN | $26.83 B | -51.33% | 🇺🇸 USA |
 Biogen BIIB | $9.99 B | -81.88% | 🇺🇸 USA |
 Gilead Sciences GILD | $27.39 B | -50.32% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | $44.93 B | -18.50% | 🇺🇸 USA |
 AstraZeneca AZN | $44.99 B | -18.40% | 🇬🇧 UK |
 GlaxoSmithKline GSK | $36.53 B | -33.73% | 🇬🇧 UK |
 Neurocrine Biosciences
NBIX | $1.78 B | -96.76% | 🇺🇸 USA |